ROYAL BODYCARE INC/NV - 8-K


______________________RBC Life Sciences, Inc.______________________ (Exact name of registrant as specified in its charter)
_______NEVADA_______ (State or other jurisdiction of incorporation)	_______000-50417_________ (Commission File Number)	_______91-2015186________ (IRS Employer Identification No.)
2301 CROWN COURT, IRVING, TEXAS (Address of principal executive offices)		____________75038_____________ (Zip Code)
Registrant's telephone number, including area code __________972-893-4000______________
__________________________N/A____________________________ (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On March 8, 2011, RBC Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2010. A copy of the press release is being furnished as Exhibit 99.1 to this Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, this information, including the exhibit related hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Irving, Texas (RBC Life Sciences: OTCBB: RBCL) - RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported a 13% increase in consolidated net sales to $28.2 million for the year ended December 31, 2010, compared to net sales of $24.9 million for the same period during 2009. For 2010, the Company reported net earnings of $558,000, or $0.02 per diluted share, compared to a net loss of $335,000, or $0.02 per diluted share, during 2009.

“We significantly improved our financial performance in 2010 reporting sales growth in both our Nutritional Products segment and Medical Products segment,” said RBC Life Sciences President and CEO, Clinton H. Howard. “We were particularly pleased to report sales growth of 22% to our international licensees, which is our largest revenue channel. This growth in sales along with expense reductions affected during 2010 resulted in an $893,000 improvement in net operating results and a return to profitability in 2010.”

Through wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.


	Years Ended December 31,
	2010		2009
Net sales	$	28,157	$	24,925
Gross profit	13,686		12,802
Operating profit (loss)	1,044		(160		)
Earnings (loss) before income taxes	891		(324		)
Provision for income taxes	333		11
Net earnings (loss)	558		(335		)

Earnings (loss) per share - basic	$	0.03	$	(0.02	)
Earnings (loss) per share - diluted	0.02		(0.02		)

Weighted average shares outstanding - basic	21,999		21,921
Weighted average shares outstanding - diluted	22,436		21,921


	December 31,
	2010		2009
Assets
Cash and cash equivalents	$	4,220	$	3,972
Inventories	5,343		5,344
Other current assets	1,696		1,914
Total current assets	11,259		11,230
Other assets	7,085		7,383
Total assets	$	18,344	$	18,613

Liabilities and shareholders' equity
Accounts payable and accrued liabilities	$	3,087	$	2,729
Deferred revenue	2,490		3,669
Other current liabilities	168		156
Total current liabilities	5,745		6,554
Other liabilities	2,723		2,840
Shareholders' equity	9,876		9,219
Total liabilities and shareholders' equity	$	18,344	$	18,613


Exhibit Number	Description
99.1	Press release dated March 8, 2011, announcing financial results for the year ended December 31, 2010